Back to top
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 30% (75 out of 250)Zacks Sector Rank
Top 25% (4 out of 16)Premium Research: Industry Analysis
| Top Peers | Symbol | Zacks Rank |
|---|---|---|
| Atara Biotherapeutics | ATRA |  |
| BRIACELL THERAP | BCTX | |
| Beyond Air | XAIR | |
| Compugen | CGEN | |
| Cybin Inc. | CYBN | |
| Cyclacel Pharmaceuticals | CYCC | |
| Edgewise Therapeutics | EWTX | |
| Entrada Therapeutics | TRDA | |
| Halozyme Therapeutics | HALO | |
| LAVA Therapeutics | LVTX | |
Recommendations and Estimates
| Company | Industry | SP500 | |
|---|---|---|---|
| Average Recommendation (1=Buy, 5=Sell) | 1.00 | 1.35 | 9.99 |
| Current Quarter Estimate | -0.07 | 7.43 | 61.00 |
| Year Ago Quarter Estimate | -0.13 | 0.12 | 54.84 |
| Next Quarter Estimate | -0.06 | 7.81 | 63.00 |
| Next Year Estimate | -0.24 | 37.76 | 270.00 |
Growth Rates
| Company | Industry | SP500 | |
|---|---|---|---|
| This Year | 45.10 | 15.40 | 15.67 |
| Next Year | 14.29 | 10.20 | 9.31 |
| Last 5 Years | NA | 1.00 | 8.10 |
| Next 5 Years | NA | 20.40 | NA |
Financials
| Company | Industry | |
|---|---|---|
| Price/Earnings (TTM) | NA | -2.18 |
| Price/Book (MRQ) | NA | 1.88 |
| Price/Cash Flow (MRFY) | NA | 15.95 |
| Dividend Yield | 0.00% | 0.00% |
| Net Profit Margin (TTM) | NA | -100.57% |
| Return on Equity (TTM) | NA | -21.50% |
| Debt to Equity (MRQ) | NA | 0.13 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.